JPMorgan Chase lowers Anthem stock to ‘neutral’

Equity researches at JPMorgan Chase downgraded payer Anthem’s stock from an “overweight” rating to a “neutral” rating Monday, according to Community Financial News.  

Advertisement

The downgrade means Anthem stock is expected to perform in line with its average return of stock, rather than outperform its average return of stock as projected.

Indianapolis-based Anthem — which has a 52-week low of $115.63 and a 52-week high of $149.50 — opened at $121.09 Monday.  

More articles about payer issues:
Update: Insurers weigh in on civil rights allegations over HIV drug coverage
11.7 million uninsured eligible for Medicaid, tax credits under ACA
Regulators approve double-digit health plan rate hikes for Illinois

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Capital

Advertisement

Comments are closed.